First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3019
Dean Anthony Fennell ₁ , Sean Dulloo ₁ , Simon Lord ₂ , Fiona Thistlethwaite ₃ , Kevin G Blyth ₄ , Peter Wojciech Szlosarek ₅ , Nick Maskell ₆ , Sanjay Popat ₇ , Avinash Aujayeb ₈ , Burak Y Aktas ₉ , Sohail Rooman Javed ₁₀ , Julio Herrero Colomina ₃ , Brian Cunniff ₁₁ , Jarrett Duncan ₁₂ , Philippa Graham ₁₃ , Alice Susannah Bexon ₁₃ , George N Naumov ₁₂ , James F. Spicer ₁₄

Affiliation

Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
University of Oxford, Oxford, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
University of Glasgow, Glasgow, United Kingdom
Barts Cancer Centre, London, United Kingdom
University of Bristol, Bristol, United Kingdom
The Royal Marsden NHS Foundation Trust, London, United Kingdom
Respiratory Department, Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Oxford University, Oxford, United Kingdom
University of Vermont, Larner College of Medicine, Burlington, VT
RS Oncology LLC, Cambridge, MA
Bexon Clinical Consulting, LLC, Montclair, NJ
King's College London, London, United Kingdom